Advancements in Dermatology: A Weekly Review
Dermatologia e Venerologia
Breakthroughs in Inflammatory Skin Diseases and Novel Therapies
This week we explore groundbreaking research in inflammatory skin diseases, including novel biologics for urticaria and hidradenitis suppurativa, phenotype switching between psoriasis and atopic dermatitis, and innovative treatments for alopecia and chronic hand eczema.
Accedi o Registrati per ascoltare questo episodio
Bibliografia
1. Randomized dose-finding study of anti-KIT barzolvolimab in patients with chronic spontaneous urticaria.
Authors: Metz M, Mitha E, Leflein J, et al.
Journal: The Journal of allergy and clinical immunology, 2026 Nov
PMID: 41747871
DOI: 10.1016/j.jaci.2026.02.018
2. Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody.
Authors: Sun Y, Mi Z, Yu Y, et al.
Journal: Signal transduction and targeted therapy, 2026 Oct 14
PMID: 42869887
DOI: 10.1038/s41392-026-02886-z
3. Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study.
Authors: Kern JS, Thomsen SF, Kokolakis G, et al.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 Nov
PMID: 42478283
DOI: 10.1111/jdv.70594
4. Treatment-associated phenotype switching between psoriasis and atopic dermatitis.
Authors: Torres T, Valenti M, Balato A, et al.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 Nov
PMID: 42132049
DOI: 10.1111/jdv.70503
5. Smartphone Applications in Dermatology With Special Focus on AI: A European-Continent-Based Review.
Authors: Sangers T, Shifai AN, Pasqualini DGJ, et al.
Journal: International journal of dermatology, 2026 Nov
PMID: 42458765
DOI: 10.1111/ijd.70582
6. Molecular Biomarkers Linking Psoriasis and Cardiovascular Disease: Current Evidence and Clinical Perspectives.
Authors: Matwiejuk M, Myśliwiec H, Mikłosz A, et al.
Journal: International journal of molecular sciences, 2026 Oct 8
PMID: 42884160
DOI: 10.3390/ijms27198918
7. Thulium laser-assisted delivery of growth factors for treating androgenetic alopecia - a randomized, controlled, clinical study.
Authors: Nguyen L, Schneider SW, Herberger K
Journal: Lasers in medical science, 2026 Oct 22
PMID: 42911445
DOI: 10.1007/s10103-026-05066-1
8. Efficacy and Safety of Delgocitinib and Its Impact on Patient's Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study.
Authors: Pezzolo E, Luyo Saboya RA, Ortoncelli M, et al.
Journal: Acta dermato-venereologica, 2026 Oct 7
PMID: 42839349
DOI: 10.2340/actadv.v106.adv-2026-0765
9. Predictors of immunological non-response despite virological suppression in people living with HIV on antiretroviral therapy: A systematic review and meta-analysis.
Authors: Rachman BE, Supranoto YTN, Nurannisa FR, et al.
Journal: PloS one, 2026
PMID: 42862878
DOI: 10.1371/journal.pone.0358793
10. Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial.
Authors: Riemer R, Braun LM, Giesler S, et al.
Journal: Nature communications, 2026 Oct 23
PMID: 42919851
DOI: 10.1038/s41467-026-78897-9
Authors: Metz M, Mitha E, Leflein J, et al.
Journal: The Journal of allergy and clinical immunology, 2026 Nov
PMID: 41747871
DOI: 10.1016/j.jaci.2026.02.018
2. Targeting an IL-17/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody.
Authors: Sun Y, Mi Z, Yu Y, et al.
Journal: Signal transduction and targeted therapy, 2026 Oct 14
PMID: 42869887
DOI: 10.1038/s41392-026-02886-z
3. Safety and pharmacokinetics of anumigilimab for hidradenitis suppurativa or palmoplantar pustulosis: A phase 1b study.
Authors: Kern JS, Thomsen SF, Kokolakis G, et al.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 Nov
PMID: 42478283
DOI: 10.1111/jdv.70594
4. Treatment-associated phenotype switching between psoriasis and atopic dermatitis.
Authors: Torres T, Valenti M, Balato A, et al.
Journal: Journal of the European Academy of Dermatology and Venereology : JEADV, 2026 Nov
PMID: 42132049
DOI: 10.1111/jdv.70503
5. Smartphone Applications in Dermatology With Special Focus on AI: A European-Continent-Based Review.
Authors: Sangers T, Shifai AN, Pasqualini DGJ, et al.
Journal: International journal of dermatology, 2026 Nov
PMID: 42458765
DOI: 10.1111/ijd.70582
6. Molecular Biomarkers Linking Psoriasis and Cardiovascular Disease: Current Evidence and Clinical Perspectives.
Authors: Matwiejuk M, Myśliwiec H, Mikłosz A, et al.
Journal: International journal of molecular sciences, 2026 Oct 8
PMID: 42884160
DOI: 10.3390/ijms27198918
7. Thulium laser-assisted delivery of growth factors for treating androgenetic alopecia - a randomized, controlled, clinical study.
Authors: Nguyen L, Schneider SW, Herberger K
Journal: Lasers in medical science, 2026 Oct 22
PMID: 42911445
DOI: 10.1007/s10103-026-05066-1
8. Efficacy and Safety of Delgocitinib and Its Impact on Patient's Perspective for Moderate-to-severe Chronic Hand Eczema in Adults: A 16-week Real-world Prospective Multicentre Study.
Authors: Pezzolo E, Luyo Saboya RA, Ortoncelli M, et al.
Journal: Acta dermato-venereologica, 2026 Oct 7
PMID: 42839349
DOI: 10.2340/actadv.v106.adv-2026-0765
9. Predictors of immunological non-response despite virological suppression in people living with HIV on antiretroviral therapy: A systematic review and meta-analysis.
Authors: Rachman BE, Supranoto YTN, Nurannisa FR, et al.
Journal: PloS one, 2026
PMID: 42862878
DOI: 10.1371/journal.pone.0358793
10. Extracorporeal photopheresis for the treatment of steroid-refractory immune related adverse events from immune checkpoint inhibitor therapy: a multi-center phase Ib/II clinical trial.
Authors: Riemer R, Braun LM, Giesler S, et al.
Journal: Nature communications, 2026 Oct 23
PMID: 42919851
DOI: 10.1038/s41467-026-78897-9
